Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration
Gary D NovackVolume:
130
Year:
2000
Language:
english
DOI:
10.1016/s0002-9394(00)00579-1
File:
PDF, 159 KB
english, 2000